Book HBeAg Test in Muzaffarpur | Hepatitis B Envelope Antigen Test

The Hepatitis B Envelope Antigen test is a blood test that detects the presence of HBeAg, a soluble protein secreted into the bloodstream by hepatitis B virus-infected hepatocytes during active viral replication. HBeAg is derived from the precore and core regions of the hepatitis B virus genome and its presence in the blood serves as a direct marker of high-level viral replication activity and significant infectivity. When HBeAg is detectable in the serum of a person with chronic hepatitis B infection, it indicates that the virus is actively replicating at high levels, the liver is being subjected to ongoing immune-mediated damage, and the risk of transmitting the infection to others is substantially elevated. The HBeAg test is interpreted in clinical context alongside HBsAg, anti-HBe antibodies, HBV DNA viral load, and liver function tests to stage the phase of chronic hepatitis B infection. Chronic hepatitis B naturally evolves through distinct immunological phases including the immune tolerant phase with high HBeAg and high viral load but minimal liver inflammation, the immune active or HBeAg-positive hepatitis phase with active liver damage, the inactive carrier phase following HBeAg seroconversion when HBeAg is lost and anti-HBe develops, and in some patients a subsequent HBeAg-negative hepatitis phase driven by precore mutant virus strains that replicate actively without producing HBeAg. India has an intermediate to high hepatitis B endemicity, with an estimated 40 million chronic hepatitis B carriers representing approximately three percent of the population. HBeAg testing is a cornerstone of chronic hepatitis B management in India, guiding antiviral treatment initiation, monitoring treatment response, and assessing transmission risk. The test is performed on a small blood sample drawn from a vein and completed in under five minutes.

Doctors prescribe an HBeAg test in the following situations: Staging chronic hepatitis B infection in patients with confirmed HBsAg positivity where HBeAg status distinguishes the high replication HBeAg-positive phase from the lower replication HBeAg-negative phases, fundamentally determining the urgency of antiviral treatment initiation and the intensity of liver disease monitoring required. Assessing infectivity and transmission risk in chronic hepatitis B carriers where HBeAg positivity indicates high viral replication and significantly elevated risk of horizontal and vertical transmission, informing counselling regarding safe sex practices, household contact vaccination, and mother-to-child transmission prevention strategies. Guiding antiviral treatment decisions in chronic hepatitis B where HBeAg positivity alongside elevated HBV DNA and raised ALT is one of the primary indications for initiating nucleoside analogue therapy with tenofovir or entecavir under hepatologist supervision as per current international treatment guidelines. Monitoring antiviral treatment response in HBeAg-positive chronic hepatitis B patients where HBeAg seroconversion, defined as loss of HBeAg and development of anti-HBe antibodies, is a major virological milestone indicating immune control of viral replication and a key endpoint guiding decisions regarding treatment duration and possible discontinuation. Evaluating pregnant women with chronic hepatitis B where HBeAg positivity in the mother is associated with very high rates of perinatal transmission to the newborn despite standard immunoprophylaxis, and where antiviral therapy in the third trimester is recommended to further reduce viral load and transmission risk. Investigating unexplained elevated liver enzymes and chronic liver disease in patients with known or newly diagnosed hepatitis B where HBeAg status forms an essential part of the complete hepatitis B serological profile required to determine disease phase, prognosis, and the need for liver biopsy or non-invasive fibrosis assessment.

The HBeAg test detects the presence or absence of Hepatitis B Envelope Antigen in the blood serum, reported as reactive or non-reactive. Some laboratory platforms also provide a quantitative index value or signal-to-cutoff ratio that correlates broadly with the level of antigen present, though HBeAg quantification is less standardised than HBV DNA quantification. Non-Reactive A non-reactive HBeAg result indicates that the envelope antigen is not detectable in the blood at the time of testing. In a patient with chronic hepatitis B, a non-reactive HBeAg may indicate the inactive carrier phase following successful seroconversion, HBeAg-negative hepatitis driven by precore mutant virus, or very early infection before peak antigen production. Clinical correlation with anti-HBe, HBV DNA, and liver function tests is essential for accurate phase determination. Reactive HBeAg with Low to Moderate HBV DNA A reactive HBeAg result with relatively lower HBV DNA levels may be seen in the early immune tolerant phase in younger patients or during the transition toward immune active disease. This combination requires close monitoring with serial liver function tests, HBV DNA quantification, and liver disease assessment to determine whether antiviral treatment is currently indicated or whether continued surveillance is appropriate. Reactive HBeAg with High HBV DNA A reactive HBeAg result alongside high HBV DNA, typically above 20,000 IU/mL, and elevated ALT indicates active HBeAg-positive hepatitis with significant liver damage from ongoing immune-mediated viral clearance attempts. This combination represents one of the clearest indications for antiviral therapy initiation and requires prompt hepatologist review for treatment planning and liver fibrosis assessment.

No fasting is required for the HBeAg test, as food and fluid intake do not affect hepatitis B antigen concentrations in the blood. The test can be performed at any time of day and is typically ordered as part of a comprehensive hepatitis B serological panel without any specific dietary preparation needed beforehand. Inform your doctor about all medications currently being taken, particularly antiviral agents including tenofovir, entecavir, lamivudine, and interferon, as ongoing antiviral therapy directly suppresses viral replication and can influence HBeAg levels and the interpretation of seroconversion status during treatment monitoring. Accurate medication history is essential for contextualising results correctly in the treatment monitoring setting. If the test is being performed as part of a pre-treatment baseline assessment, inform your doctor about any recent acute illnesses, immunosuppressive therapy, or chemotherapy, as these can transiently alter hepatitis B serological markers and affect the accuracy of phase determination. Staying well hydrated before the blood draw facilitates easier venous access and a smooth collection experience, particularly when HBeAg is ordered alongside a full hepatitis B panel including HBV DNA quantification and liver function tests.

If you are booking through the SecondMedic platform the HBeAg test price in Muzaffarpur can cost you around Rs. 957. You may also consider booking a comprehensive hepatitis B panel that includes HBeAg alongside HBsAg, anti-HBe, anti-HBs, HBV DNA quantification, and liver function tests for a complete assessment of hepatitis B disease phase and liver health at a bundled price on SecondMedic.

SecondMedic offers convenient home sample collection for the HBeAg test in Muzaffarpur, making it easy to get tested without visiting a diagnostic centre. Home collection is available free of charge for orders above Rs. 300. A trained phlebotomist will visit your preferred address between 7 AM and 10 PM, seven days a week, including Sundays and public holidays. Your blood sample is processed at NABL-accredited partner laboratories, and your report is delivered within 24 hours directly to your WhatsApp and email.